Published in Am J Psychiatry on October 01, 2005
Biomarkers of Conversion Risk and Treatment Response in Early-Stage Schizophrenia | NCT03323437
OnTrack>An Online Role-Playing Game for Young People With First Episode Psychosis | NCT03390491
Early intervention services, cognitive-behavioural therapy and family intervention in early psychosis: systematic review. Br J Psychiatry (2010) 2.73
Use of neuroanatomical pattern classification to identify subjects in at-risk mental states of psychosis and predict disease transition. Arch Gen Psychiatry (2009) 2.17
Early intervention in psychosis: concepts, evidence and future directions. World Psychiatry (2008) 2.17
First aid recommendations for psychosis: using the Delphi method to gain consensus between mental health consumers, carers, and clinicians. Schizophr Bull (2007) 2.09
The Information Technology Aided Relapse Prevention Programme in Schizophrenia: an extension of a mirror-design follow-up. Int J Clin Pract (2008) 1.66
Cognitive enhancement therapy for early-course schizophrenia: effects of a two-year randomized controlled trial. Psychiatr Serv (2009) 1.62
A systematic review and meta-analysis of recovery in schizophrenia. Schizophr Bull (2012) 1.43
The key to reducing duration of untreated first psychosis: information campaigns. Schizophr Bull (2007) 1.41
Pathways to psychiatric care for mental disorders: a retrospective study of patients seeking mental health services at a public psychiatric facility in Ghana. Int J Ment Health Syst (2016) 1.39
Schizophrenia. BMJ (2007) 1.37
Research in people with psychosis risk syndrome: a review of the current evidence and future directions. J Child Psychol Psychiatry (2010) 1.36
What we know: findings that every theory of schizophrenia should explain. Schizophr Bull (2009) 1.27
Cognition, function, and disability in patients with schizophrenia: a review of longitudinal studies. Can J Psychiatry (2014) 1.25
Towards a psychosis risk blood diagnostic for persons experiencing high-risk symptoms: preliminary results from the NAPLS project. Schizophr Bull (2014) 1.23
Trajectory to a first episode of psychosis: a qualitative research study with families. Early Interv Psychiatry (2007) 1.14
Meta-analysis of the Interval between the Onset and Management of Bipolar Disorder. Can J Psychiatry (2016) 1.11
Renaming schizophrenia. BMJ (2007) 1.10
Early signs, diagnosis and therapeutics of the prodromal phase of schizophrenia and related psychotic disorders. Expert Rev Neurother (2010) 1.10
The period of untreated psychosis before treatment initiation: a qualitative study of family members' perspectives. Compr Psychiatry (2008) 1.10
Who is paying the price? Loss of health insurance coverage early in psychosis. Psychiatr Serv (2011) 1.07
Glutamatergic dysfunction in schizophrenia: from basic neuroscience to clinical psychopharmacology. Eur Neuropsychopharmacol (2008) 1.06
Duration of untreated psychosis and social function: 1-year follow-up study of first-episode schizophrenia. Br J Psychiatry (2008) 1.05
Covert treatment in psychiatry: do no harm, true, but also dare to care. Mens Sana Monogr (2008) 1.05
Do we have any solid evidence of clinical utility about the pathophysiology of schizophrenia? World Psychiatry (2011) 1.04
Pharmacogenetics in psychiatry: are we ready for widespread clinical use? Schizophr Bull (2008) 1.02
Stigma and treatment delay in first-episode psychosis: a grounded theory study. Early Interv Psychiatry (2010) 1.00
Mismatch negativity as a "translatable" brain marker toward early intervention for psychosis: a review. Front Psychiatry (2013) 0.99
La CLAve to increase psychosis literacy of Spanish-speaking community residents and family caregivers. J Consult Clin Psychol (2009) 0.98
Family-level predictors and correlates of the duration of untreated psychosis in African American first-episode patients. Schizophr Res (2009) 0.97
Which pathways to psychiatric care lead to earlier treatment and a shorter duration of first-episode psychosis? BMC Psychiatry (2014) 0.96
Disease prediction in the at-risk mental state for psychosis using neuroanatomical biomarkers: results from the FePsy study. Schizophr Bull (2011) 0.96
Early cognitive experience prevents adult deficits in a neurodevelopmental schizophrenia model. Neuron (2012) 0.95
A meta-analysis of ethnic differences in pathways to care at the first episode of psychosis. Acta Psychiatr Scand (2014) 0.95
Mismatch negativity and cognitive performance for the prediction of psychosis in subjects with at-risk mental state. PLoS One (2013) 0.95
Pathways from cannabis to psychosis: a review of the evidence. Front Psychiatry (2013) 0.94
Service user and carer experiences of seeking help for a first episode of psychosis: a UK qualitative study. BMC Psychiatry (2011) 0.94
Oil and water or oil and vinegar? Evidence-based medicine meets recovery. Community Ment Health J (2009) 0.94
Psychopharmacology of schizophrenia: The Future Looks Bleak. Mens Sana Monogr (2012) 0.93
Ethnic variations in compulsory detention and hospital admission for psychosis across four UK Early Intervention Services. BMC Psychiatry (2014) 0.92
Is early intervention for psychosis feasible and effective? Psychiatr Clin North Am (2012) 0.91
Toward the identification of peripheral epigenetic biomarkers of schizophrenia. J Neurogenet (2014) 0.91
Exploring predictors of outcome in the psychosis prodrome: implications for early identification and intervention. Neuropsychol Rev (2009) 0.89
Duration of untreated psychosis is associated with temporal and occipitotemporal gray matter volume decrease in treatment naïve schizophrenia. PLoS One (2013) 0.89
Detection of psychosis by mental health care services; a naturalistic cohort study. Clin Pract Epidemiol Ment Health (2008) 0.88
Untreated illness duration correlates with gray matter loss in first-episode psychoses. Neuroreport (2009) 0.88
Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia. Neuropsychiatr Dis Treat (2012) 0.88
Prodromal schizophrenia in primary care: a randomised sensitisation study. Br J Gen Pract (2010) 0.88
Unmet needs in the management of schizophrenia. Neuropsychiatr Dis Treat (2014) 0.88
Review of the operational definition for first-episode psychosis. Early Interv Psychiatry (2009) 0.88
Specificity of Incident Diagnostic Outcomes in Patients at Clinical High Risk for Psychosis. Schizophr Bull (2015) 0.87
The heterogeneity of antipsychotic response in the treatment of schizophrenia. Psychol Med (2010) 0.87
The Pathways to the First Contact with Mental Health Services among Patients with Schizophrenia in Lagos, Nigeria. Schizophr Res Treatment (2013) 0.87
Services for people at high risk improve outcomes in patients with first episode psychosis. Acta Psychiatr Scand (2015) 0.87
Perceptions about the cause of schizophrenia and the subsequent help seeking behavior in a Pakistani population - results of a cross-sectional survey. BMC Psychiatry (2008) 0.87
Cluster analysis of cognitive deficits may mark heterogeneity in schizophrenia in terms of outcome and response to treatment. Eur Arch Psychiatry Clin Neurosci (2013) 0.87
Does duration of untreated psychosis predict very long term outcome of schizophrenic disorders? results of a retrospective study. Ann Gen Psychiatry (2012) 0.86
The role of untreated psychosis in neurodegeneration: a review of hypothesized mechanisms of neurotoxicity in first-episode psychosis. Can J Psychiatry (2014) 0.86
Race, ethnicity, and the duration of untreated psychosis: a systematic review. Soc Psychiatry Psychiatr Epidemiol (2013) 0.85
Early intervention in psychotic disorders: Challenges and relevance in the Indian context. Indian J Psychiatry (2010) 0.85
Patient and prescriber perspectives on long-acting injectable (LAI) antipsychotics and analysis of in-office discussion regarding LAI treatment for schizophrenia. BMC Psychiatry (2013) 0.85
Characterization of the deficit syndrome in drug-naive schizophrenia patients: the role of spontaneous movement disorders and neurological soft signs. Schizophr Bull (2012) 0.85
Abnormal causal connectivity by structural deficits in first-episode, drug-naive schizophrenia at rest. Schizophr Bull (2014) 0.85
Tolerability of initiation doses of once-monthly paliperidone palmitate in patients with recently diagnosed schizophrenia in an acute treatment trial. Ther Adv Psychopharmacol (2011) 0.84
Prevalence and psychosocial correlates of prior incarcerations in an urban, predominantly African-American sample of hospitalized patients with first-episode psychosis. J Am Acad Psychiatry Law (2011) 0.83
Social Cognition in Individuals at Ultra-High Risk for Psychosis: A Meta-Analysis. PLoS One (2015) 0.83
Developing services for the early detection of psychosis: a critical consideration of the current state of the art. Eur Child Adolesc Psychiatry (2006) 0.83
A snapshot of plasma metabolites in first-episode schizophrenia: a capillary electrophoresis time-of-flight mass spectrometry study. Transl Psychiatry (2014) 0.83
Mismatch negativity and p3a/reorienting complex in subjects with schizophrenia or at-risk mental state. Front Behav Neurosci (2014) 0.83
Increased Cerebellar Functional Connectivity With the Default-Mode Network in Unaffected Siblings of Schizophrenia Patients at Rest. Schizophr Bull (2015) 0.83
Pathways to First-Episode Care for Psychosis in African-, Caribbean-, and European-Origin Groups in Ontario. Can J Psychiatry (2015) 0.83
Are the effects of duration of untreated psychosis socially mediated? Can J Psychiatry (2014) 0.82
The case for early, medium and late intervention in psychosis. World Psychiatry (2008) 0.82
Treatment implications of the schizophrenia prodrome. Curr Top Behav Neurosci (2010) 0.82
Genealogy of instruments for prodrome evaluation of psychosis. Front Psychiatry (2013) 0.82
Demographic, socio-environmental, and substance-related predictors of duration of untreated psychosis (DUP). Schizophr Res (2013) 0.82
G72 influences longitudinal change in frontal lobe volume in schizophrenia. Am J Med Genet B Neuropsychiatr Genet (2010) 0.81
Prognostic value of duration of untreated psychosis in long-term outcome of schizophrenia. Med Sci Monit (2011) 0.81
What is schizophrenia: A neurodevelopmental or neurodegenerative disorder or a combination of both? A critical analysis. Indian J Psychiatry (2010) 0.81
Premorbid adjustment, onset types, and prognostic scaling: still informative? Schizophr Bull (2008) 0.81
Health states for schizophrenia and bipolar disorder within the Global Burden of Disease 2010 Study. Popul Health Metr (2012) 0.81
The Amsterdam Studies of Acute Psychiatry I (ASAP-I); a prospective cohort study of determinants and outcome of coercive versus voluntary treatment interventions in a metropolitan area. BMC Psychiatry (2008) 0.80
Clinical predictors of therapeutic response to antipsychotics in schizophrenia. Dialogues Clin Neurosci (2014) 0.80
Effect of an education program on improving help-seeking among parents of junior and senior high school students in Japan. Glob J Health Sci (2011) 0.80
Prevention of the first episode of psychosis. Psychiatr Clin North Am (2010) 0.80
Early intervention in schizophrenia. Indian J Psychiatry (2008) 0.80
Gray matter changes in subjects at high risk for developing psychosis and first-episode schizophrenia: a voxel-based structural MRI study. Front Psychiatry (2013) 0.80
Onset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: post-hoc analyses of a randomized, double-blind clinical trial. BMC Psychiatry (2011) 0.80
Personality domains, duration of untreated psychosis, functioning, and symptom severity in first-episode psychosis. Schizophr Res (2015) 0.79
Youth-caregiver agreement on clinical high-risk symptoms of psychosis. J Abnorm Child Psychol (2014) 0.79
Gender difference in the prodromal symptoms of first-episode schizophrenia. J Korean Med Sci (2009) 0.79
Antipsychotic agents: efficacy and safety in schizophrenia. Drug Healthc Patient Saf (2012) 0.79
Evaluation of a community awareness programme to reduce delays in referrals to early intervention services and enhance early detection of psychosis. BMC Psychiatry (2015) 0.78
Predictors of outcome in early-onset psychosis: a systematic review. NPJ Schizophr (2015) 0.78
Rates of first episode of psychosis in a defined catchment area in Greece. Clin Pract Epidemiol Ment Health (2013) 0.78
Motor agency: a new and highly sensitive measure to reveal agency disturbances in early psychosis. PLoS One (2012) 0.77
Risk of Schizophrenia Increases After All Child and Adolescent Psychiatric Disorders: A Nationwide Study. Schizophr Bull (2014) 0.77
Pathways to care: duration of untreated psychosis from Karachi, Pakistan. PLoS One (2009) 0.77
Prospective study of duration of untreated psychosis and outcome of never-treated patients with schizophrenia in India. Indian J Psychiatry (2011) 0.77
Early Recognition of High Risk of Bipolar Disorder and Psychosis: An Overview of the ZInEP "Early Recognition" Study. Front Public Health (2014) 0.76
Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med (2006) 10.89
Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet (2013) 8.02
Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry (2004) 6.40
Microduplications of 16p11.2 are associated with schizophrenia. Nat Genet (2009) 6.13
Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry (2007) 5.64
Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry (2002) 5.14
Boundary and medial shape analysis of the hippocampus in schizophrenia. Med Image Anal (2004) 4.25
The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull (2003) 4.13
Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry (2006) 4.12
Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch Gen Psychiatry (2005) 3.78
Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. Am J Psychiatry (2013) 3.69
Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies. Br J Psychiatry (2006) 3.66
Physical health monitoring of patients with schizophrenia. Am J Psychiatry (2004) 3.54
Clozapine v. chlorpromazine in treatment-naive, first-episode schizophrenia: 9-year outcomes of a randomised clinical trial. Br J Psychiatry (2011) 3.49
Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry (2008) 3.48
Differences in white matter fiber tract development present from 6 to 24 months in infants with autism. Am J Psychiatry (2012) 3.38
Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry (2008) 3.30
Comparison of quetiapine and risperidone in the treatment of schizophrenia: A randomized, double-blind, flexible-dose, 8-week study. J Clin Psychiatry (2006) 3.28
Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry (2007) 3.21
Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry (2006) 3.12
A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res (2005) 2.91
Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges. J Clin Psychiatry (2008) 2.86
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. Am J Psychiatry (2007) 2.75
Morphometric analysis of lateral ventricles in schizophrenia and healthy controls regarding genetic and disease-specific factors. Proc Natl Acad Sci U S A (2005) 2.73
Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology (2006) 2.70
Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Am J Psychiatry (2007) 2.68
Regional gray matter growth, sexual dimorphism, and cerebral asymmetry in the neonatal brain. J Neurosci (2007) 2.61
Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res (2006) 2.60
Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry (2002) 2.52
Effectiveness of switching antipsychotic medications. Am J Psychiatry (2006) 2.38
Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver. Neuron (2013) 2.32
A national study of violent behavior in persons with schizophrenia. Arch Gen Psychiatry (2006) 2.23
Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry (2007) 2.22
Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia. Br J Psychiatry (2008) 2.10
First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophr Res (2004) 2.06
Identifying clinically questionable psychotropic prescribing practices for medicaid recipients in new york state. Psychiatr Serv (2009) 2.05
Teaching trainees to negotiate research collaborations with industry: a mentorship model. Am J Psychiatry (2010) 2.04
Psychosocial treatment for first-episode psychosis: a research update. Am J Psychiatry (2005) 2.03
A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia. Biol Psychiatry (2010) 1.99
Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophr Res (2008) 1.97
Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology (2003) 1.96
Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophr Res (2008) 1.95
A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am J Psychiatry (2011) 1.87
Measurement of brain metabolites by 1H magnetic resonance spectroscopy in patients with schizophrenia: a systematic review and meta-analysis. Neuropsychopharmacology (2005) 1.83
Components and correlates of family burden in schizophrenia. Psychiatr Serv (2006) 1.81
A longitudinal study of neurocognitive function in individuals at-risk for psychosis. Schizophr Res (2006) 1.81
Prenatal and neonatal brain structure and white matter maturation in children at high risk for schizophrenia. Am J Psychiatry (2010) 1.79
Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry (2003) 1.76
Quantitative tract-based white matter development from birth to age 2years. Neuroimage (2012) 1.74
Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br J Psychiatry (2005) 1.68
Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis. Am J Psychiatry (2005) 1.66
Neurocognitive correlates of the COMT Val(158)Met polymorphism in chronic schizophrenia. Biol Psychiatry (2002) 1.66
Relationship of cognition and psychopathology to functional impairment in schizophrenia. Am J Psychiatry (2008) 1.62
Neurocognitive outcomes in the Treatment of Early-Onset Schizophrenia Spectrum Disorders study. J Am Acad Child Adolesc Psychiatry (2012) 1.62
Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am J Psychiatry (2004) 1.58
Deficits in sensorimotor gating and tests of social behavior in a genetic model of reduced NMDA receptor function. Behav Brain Res (2004) 1.56
What CATIE found: results from the schizophrenia trial. Psychiatr Serv (2008) 1.55
Impact of antipsychotic medication on family burden in schizophrenia: longitudinal results of CATIE trial. Schizophr Res (2009) 1.54
Imaging frontostriatal function in ultra-high-risk, early, and chronic schizophrenia during executive processing. Arch Gen Psychiatry (2005) 1.52
Cholinergic agonists as novel treatments for schizophrenia: the promise of rational drug development for psychiatry. Am J Psychiatry (2008) 1.49
Clozapine as a first treatment for schizophrenia. Am J Psychiatry (2003) 1.49
Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. J Clin Psychiatry (2008) 1.49
Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia. J Clin Psychiatry (2010) 1.49
Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode. Schizophr Res (2005) 1.48
Association study of GSK3 gene polymorphisms with schizophrenia and clozapine response. Psychopharmacology (Berl) (2008) 1.46
Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. Schizophr Res (2002) 1.45
Longitudinal patterns of repetitive behavior in toddlers with autism. J Child Psychol Psychiatry (2014) 1.44
Cognitive development in schizophrenia: follow-back from the first episode. J Clin Exp Neuropsychol (2006) 1.42
Our future is now. Am J Psychiatry (2014) 1.39
A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropsychopharmacology (2004) 1.38
Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1. Schizophr Res (2008) 1.37
Extrapyramidal side-effects of antipsychotics in a randomised trial. Br J Psychiatry (2008) 1.37
Electrophysiological indices of automatic and controlled auditory information processing in first-episode, recent-onset and chronic schizophrenia. Biol Psychiatry (2006) 1.34
Substance use in persons with schizophrenia: baseline prevalence and correlates from the NIMH CATIE study. J Nerv Ment Dis (2006) 1.32
Apoptotic mechanisms and the synaptic pathology of schizophrenia. Schizophr Res (2005) 1.30
Brain volume findings in 6-month-old infants at high familial risk for autism. Am J Psychiatry (2012) 1.30
Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia. Schizophr Bull (2008) 1.29
The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome. Schizophr Res (2005) 1.28
Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia. Neuropsychopharmacology (2009) 1.28
Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode. Schizophr Res (2006) 1.24
White matter microstructure and atypical visual orienting in 7-month-olds at risk for autism. Am J Psychiatry (2013) 1.23
Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol. J Clin Psychopharmacol (2004) 1.23
Results of phase 3 of the CATIE schizophrenia trial. Schizophr Res (2008) 1.23
Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia. Schizophr Bull (2007) 1.21
Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophr Res (2005) 1.20
Time-lapse mapping of cortical changes in schizophrenia with different treatments. Cereb Cortex (2008) 1.20
Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia. Neuropsychopharmacology (2010) 1.19
Concurrent measurement of "real-world" stress and arousal in individuals with psychosis: assessing the feasibility and validity of a novel methodology. Schizophr Bull (2009) 1.19
Apoptotic proteins in the temporal cortex in schizophrenia: high Bax/Bcl-2 ratio without caspase-3 activation. Am J Psychiatry (2004) 1.18
Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the CAFE study. Schizophr Res (2009) 1.17
Apoptotic mechanisms in the pathophysiology of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry (2005) 1.17
Feasibility and diagnostic validity of the M-3 checklist: a brief, self-rated screen for depressive, bipolar, anxiety, and post-traumatic stress disorders in primary care. Ann Fam Med (2010) 1.16
The neurosteroid allopregnanolone is reduced in prefrontal cortex in Alzheimer's disease. Biol Psychiatry (2006) 1.15
Interrelationships of psychiatric symptom severity, medical comorbidity, and functioning in schizophrenia. Psychiatr Serv (2006) 1.12
Duration of illness and treatment effects on hippocampal volume in male patients with schizophrenia. Br J Psychiatry (2005) 1.11